ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 943

Impact of Systemic Lupus Erythematosus On Work Productivity and Income in the United States

Alan Oglesby1, Ellen Sulcs2, Siva Narayanan3, Mechele Lee2 and Cindy Garris4, 1GlaxoSmithKline, Research Triangle Park, NC, 2Healthcare Research, Harris Interactive Inc., Rochester, NY, 3Global Health Economics and Outcomes Research and Epidemiology, Human Genome Sciences, Inc., Rockville, MD, 4US Health Outcomes, GlaxoSmithKline, Research Triangle Park, NC

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research: Epidemiology and Outcomes of Rheumatic Disease II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Systemic lupus erythematosus (SLE) is a complex, chronic autoimmune disorder characterized by fluctuating periods of disease activity affecting multiple organ systems. This study was conducted to evaluate the impact of SLE on patients’ employment and productivity.

Methods: A longitudinal cohort of employed SLE patients in the United States, recruited through a patient advocacy association and the Harris Chronic Illness Panel, was surveyed online (IRB approved) between Dec 2010 and Aug 2011. Inclusion criteria were ≥18 years old, self-reported SLE diagnosis, and ≥1 SLE flare in prior 3 months requiring medical attention (taking medications, calling or visiting a physician, or going to the ER or hospital). A control group of employed patients without SLE recruited from HarrisPollOnline (HPOL) were demographically matched (age, sex, race, income, and education) to the employed SLE cohort. Controls met the above inclusion criteria excluding the SLE related criteria and were also surveyed online. A group of unemployed SLE patients were also recruited for research, but not included in this analysis of employed cohorts. Both the employed SLE patients and controls completed baseline and follow-up surveys at the end of 6 months.  Questions for the SLE cohort included perceived SLE disease activity over the past 3 months using a 10-point scale (mild: 0-3, moderate: 4-6, severe: 7-10), impact of SLE on work productivity and absenteeism. The control group answered similar questions about the impact of any health conditions on work.  Employed and unemployed SLE patients were compared to controls by dependent sample t-tests.

Results: 281 employed SLE patients and 300 employed controls completed the survey; of the 300 control group respondents, 69% reported having ≥1 health condition(s). The mean age in the employed SLE group and control groups was 39.8 and 41.1 years, respectively (p<0.05). Of all surveyed respondents, 96% were female and 79% were Caucasian (no significant differences across groups). The employed SLE cohort reported fewer overall hours worked per week (25.3 vs 32.8) and more lost work hours per week due to SLE (6.9 hours) than the employed control group due to any health condition (1.6 hours)(all p-values<0.05).  While at work, patients reported significantly greater impact on productivity due to SLE (45%) compared to controls for any health reason (13%, p<0.05).  In the SLE employed group, the number of work hours missed increased as self-reported disease severity worsened from mild, moderate, to severe (2.0, 4.2, and 7.9 hours, respectively (p<0.05). Hourly employees with SLE (52.3% of SLE cohort) reported losing an average of $346 per week due to their lupus.  Similarly, lost income per week increased as SLE activity increased ($49 in mild to $522 in severe, p<0.05).

Conclusion: Patients with SLE reported significantly reduced ability to work compounded by worsening disease activity. For hourly employees with SLE, increased disease activity may have significant detrimental impacts to their earning potential.


Disclosure:

A. Oglesby,

GlaxoSmithKline,

1,

GlaxoSmithKline,

3;

E. Sulcs,

Harris Interactive,

3;

S. Narayanan,

Human Genome Sciences, Inc,

1,

Human Genome Sciences, Inc.,

3;

M. Lee,

Harris Interactive,

3;

C. Garris,

GlaxoSmithKline,

1,

GlaxoSmithKline,

3.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-systemic-lupus-erythematosus-on-work-productivity-and-income-in-the-united-states/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology